Please ensure Javascript is enabled for purposes of website accessibility

Why Rigel Pharmaceuticals Stock Is Jumping Today

By Keith Speights - Updated Feb 18, 2021 at 12:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is teaming up with Eli Lilly on the development of a promising immune disease drug.

What happened

Shares of Rigel Pharmaceuticals (RIGL -0.50%) were jumping 10.3% as of 12:30 p.m. EST. The gain came after Rigel and Eli Lilly (LLY 0.97%) announced a collaboration to develop and market Rigel's experimental drug R552.

So what

Rigel will receive an up-front payment of $125 million from Lilly under the new agreement. In addition, Rigel could be eligible for milestone payments of up to $835 million. The company will also receive tiered royalties from any future sales of R552, ranging from the mid-single digits to the high teens.

Scientist in a lab holding a test tube

Image source: Getty Images.

R552 inhibits RIPK1, a protein that's involved in several inflammatory cellular processes. Rigel has already completed phase 1 testing targeting immune diseases.

The partnership between Lilly and Rigel appears to be a good fit. Lilly currently markets a blockbuster autoimmune disease drug, Taltz. It's also developing several candidates targeting autoimmune diseases. R552 should be a great addition to the big drugmaker's pipeline. 

Now what

Rigel and Lilly plan to advance R552 into phase 2 testing this year. The next major catalyst for the biotech stock, though, could be the anticipated April release of top-line data from a phase 2 study conducted by the National Institutes of Health evaluating fostamatinib in treating COVID-19. Rigel also has a late-stage study underway of fostamatinib as a potential COVID-19 treatment.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Rigel Pharmaceuticals, Inc. Stock Quote
Rigel Pharmaceuticals, Inc.
$2.00 (-0.50%) $0.01
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$301.75 (0.97%) $2.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.